

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Ascletis Pharma Inc.

歌禮製藥有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 1672)

VOLUNTARY ANNOUNCEMENT

ASCLETIS ANNOUNCES POSTER PRESENTATIONS ON THE STUDY RESULTS OF ORAL SMALL MOLECULE GLP-1R AGONIST ASC30 AND ADIPOSE-TARGETED, MUSCLE-PRESERVING WEIGHT LOSS DRUG CANDIDATE ASC47 AT THE 85TH SCIENTIFIC SESSIONS OF AMERICAN DIABETES ASSOCIATION (ADA)

This announcement is made by Ascletis Pharma Inc. (the “**Company**” or “**Ascletis**”, together with its subsidiaries, the “**Group**”) on a voluntary basis for the purpose of keeping the shareholders of the Company and potential investors abreast of the latest business development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company announces that poster presentations on preliminary studies of its oral small molecule GLP-1 Receptor (GLP-1R) agonist ASC30 and adipose-targeted, muscle-preserving weight loss drug candidate ASC47 will be presented at the 85th Scientific Sessions of American Diabetes Association (ADA) in Chicago, U.S.

Details of the Poster Presentations

Poster Number: 750-P

Abstract Title: ASC30, an Oral GLP-1R Biased Small Molecule Agonist in Participants with Obesity – A First-in-Human Single Ascending Dose Study

Session Type: General Poster Session

Location: Poster Hall (Hall F1)

Presentation Time: Sunday Jun 22, 2025 12:30 PM – 1:30 PM (Chicago Time), i.e., Monday Jun 23, 2025 1:30 AM – 2:30 AM (Beijing Time)

Poster Number: 847-P

Abstract Title: ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model

Session Type: General Poster Session

Location: Poster Hall (Hall F1)

Presentation Time: Sunday Jun 22, 2025 12:30 PM – 1:30 PM (Chicago Time), i.e., Monday Jun 23, 2025 1:30 AM – 2:30 AM (Beijing Time)

About ASC30

ASC30 is an investigational GLP-1R biased small molecule agonist and has unique and differentiated properties that enable the same small molecule for both oral tablet and subcutaneous injection administrations. ASC30 is a new chemical entity (NCE), with U.S. and global compound patent protection until 2044.

About ASC47

ASC47 is an adipose-targeted, ultra-long-acting subcutaneously (SQ) injected thyroid hormone receptor beta (THR β) selective small molecule agonist, discovered and developed in-house at Ascletis. ASC47 possesses unique and differentiated properties to enable adipose targeting, resulting in dose-dependent high drug concentrations in the adipose tissue. Topline data from its Phase Ib single subcutaneous injection studies in Australia in participants with elevated low-density lipoprotein cholesterol (LDL-C) ([NCT06427590](#)) have been released. The Phase I clinical trial of ASC47 in combination with semaglutide for the treatment of obesity ([NCT06972992](#)) is ongoing in the U.S., and the first participants were dosed in May 2025.

About the American Diabetes Association (ADA)

Established in 1940, the American Diabetes Association (ADA) is dedicated to preventing and curing diabetes and to improving the lives of all people affected by diabetes. It has grown into one of the foremost nonprofit organizations in diabetes advocacy around the world. Its annual Scientific Sessions set the agenda for clinical practice and research innovation. The 85th Scientific Sessions of ADA will be held in Chicago, U.S. from June 20 to 23, 2025.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: We cannot guarantee that we will be able to ultimately develop, manufacture and/or commercialize ASC30 and/or ASC47 successfully.

By order of the Board
Ascletis Pharma Inc.
歌禮製藥有限公司
Jinzi Jason WU
Chairman

Hong Kong
June 9, 2025

As at the date of this announcement, the Board comprises Dr. Jinzi Jason WU and Mrs. Judy Hejingdao WU, as executive Directors; and Dr. Yizhen WEI, Mr. Jiong GU and Ms. Lin HUA, as independent non-executive Directors.